SN52

SN52 is a potent, competitive, and cell-permeable inhibitor of NF-κB2 . SN52 is a variant of the SN50 peptide and inhibits the nuclear translocation of p52-RelB heterodimers. SN52 has a strong radiosensitization effect on prostate cancer cells. SN52 can be used for cancer research In Vitro SN52 (40 μg/ml; 30 mins before DMXAA) inhibits DMXAA-induced nuclear translocation of RelB in BMDCs. SN52 does not change the activation of canonical NF-κB signaling. The nuclear translocation of RelB is increased in DCs isolated from irradiated tumors, and SN52 abolishes this activation in activated DC cells. SN52 (40 μg/mL; 30 mins before co-cultured with irradiated or non-irradiated MC38 cells) inhibits the non-canonical NF-κB and increases Ifn-b expression in BMDCs stimulated with irradiated tumor cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo SN52 (intrathecal injection; 40 μg/ml; day-1, day 1 and day 3 of 20Gy radiation of radiation) combines with IR enhances anti-tumor immune functions of both DCs and CD8 + T cells and subsequently reduced tumor burden more effectively compared with IR alone . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Tumor mice model Dosage: 40 μg Administration: Intrathecal injection; 40 μg; day-1, day 1 and day 3 of 20Gy radiation of radiation Result: Reduced tumor burden than IR group alone. Induced non-canonical NF-κB inhibition and potentiates the anti-tumor effect of IR. Form:Solid IC50& Target:IC50: NF-κB2

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet